Cargando…
Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study
INTRODUCTION: Type 1 diabetes (T1D) is caused by autoimmune destruction of the insulin-producing β cells in the pancreatic islets, leading to insulinopenia and hyperglycaemia. Genetic analyses indicate that alterations of the interleukin-2 (IL-2) pathway mediating immune activation and tolerance pre...
Autores principales: | Truman, Lucy A, Pekalski, Marcin L, Kareclas, Paula, Evangelou, Marina, Walker, Neil M, Howlett, James, Mander, Adrian P, Kennet, Jane, Wicker, Linda S, Bond, Simon, Todd, John A, Waldron-Lynch, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679899/ https://www.ncbi.nlm.nih.gov/pubmed/26646829 http://dx.doi.org/10.1136/bmjopen-2015-009799 |
Ejemplares similares
-
Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial
por: Waldron-Lynch, Frank, et al.
Publicado: (2014) -
Simulation work in adaptive dose-finding designs to identify dose-intervals that achieve targets in multiple endpoints
por: Howlett, James, et al.
Publicado: (2015) -
Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets
por: Bond, Simon, et al.
Publicado: (2013) -
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
por: Todd, John A., et al.
Publicado: (2016) -
Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells
por: Inaba, Akimichi, et al.
Publicado: (2023)